SCHEMBL6762007

SCHEMBL6762007

O=C(O)c1cc(Cl)ccc1OCC(=O)N1[C@@H]2CC[C@H]1CC(Oc1ccc(F)cc1)C2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 4/20 0.52
TSHR P16473 2/20 0.41
EPHX2 P34913 1/20 0.41
GAA P10253 1/20 0.40
LIPG Q9Y5X9 3/20 0.40
LIPC P11150 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
HRH1 P35367 1/20 0.38
CCR3 P51677 1/20 0.38
GRIK1 P39086 2/20 0.38
GRIA2 P42262 2/20 0.38
PTGER4 P35408 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
OPRM1 P35372 1/20 0.38
OPRK1 P41145 1/20 0.38
KCNH2 Q12809 1/20 0.38
HTR2C P28335 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6762010 1.00 CCR1 (0.52) CCR1TSHREPHX2GAALIPG
SCHEMBL6758368 0.91 CCR1 (0.43) CCR1TSHREPHX2LMNATP53
SCHEMBL6765181 0.91 NPC1 (0.47) CCR1TSHREPHX2LMNATP53
SCHEMBL6156266 0.91 CCR1 (0.43) CCR1TSHREPHX2LMNATP53
SCHEMBL6765183 0.91 NPC1 (0.47) CCR1TSHREPHX2LMNATP53
SCHEMBL6156258 0.91 CCR1 (0.43) CCR1TSHREPHX2LMNATP53
SCHEMBL6765196 0.89 CCR1 (0.44) CCR1TSHREPHX2LMNATP53
SCHEMBL6765200 0.89 CCR1 (0.44) CCR1TSHREPHX2LMNATP53
SCHEMBL6758137 0.89 CCR1 (0.45) CCR1TSHREPHX2PTGER4PTGDR2
SCHEMBL6758135 0.89 CCR1 (0.45) CCR1TSHREPHX2PTGER4PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063688-A1 Novel piperidine derivatives PFIZER INC. 2004-04-01 US claimed
US-20040063688-A1 Novel piperidine derivatives PFIZER INC. 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063688-A1 Novel piperidine derivatives CCR1, CCR3, CCR2 CCR1 1/4885TSHR 2865/4885EPHX2 3279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.